Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings In Brief: ImmunoGen's Oncolysin

Executive Summary

ImmunoGen's Oncolysin: Company notes debenture funds will "buy us more time" to figure out how to achieve the needed number of patients for its Phase III trial of Oncolysin (Mab CD19 anti-B4-blocked ricin) for treatment of B-cell lymphomas and leukemias after autologous bone marrow transplantation. ImmunoGen says it is working on options to shorten the time to completion of the pivotal trial but will need "additional funds before these studies are completed." ImmunoGen may seek a corporate partner or some other relationship, the company says. Nearly 300 patients of an original estimate of 388 have been enrolled in the study so far, the company says; however, the accrual probably will have to be higher, the firm indicates. Of 55 sites enrolling patients, 40 are currently doing so...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS026785

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel